Effect of Aspirin Dose on Preeclampsia Prevention and Fetal-maternal Complications: A Randomized Clinical Trial

Preeclampsia (PE) is a disease characterized by abnormalities in the placenta and endothelial cells. The pathogenesis is not fully understood; however, aspirin prescription can be effective to treat the disease and prevent fetal developmental disorders.

This study was performed as a clinical trial in Shahid Akbrabadi Hospital in Tehran city. Eighty patients participated in two groups (n = 40). The first group of patients received the dose of 80mg, and the second group received the dose of 160mg aspirin. Then, the fetal-maternal and treatment process complications were examined in the patients.

The results showed that the incidence of fetal-maternal complications, including intrauterine growth restriction (IUGR) and intrauterine fetal death (IUFD) was lower in patients treated with 160 mg aspirin than in the other group, but this difference was not statistically significant (P-value > 0.05). Aspirin complications such as bleeding were more in the second group than in the first one (P-value < 0.05).

Although the increasing dose of aspirin reduces fetal-maternal complications in PE patients, the problems such as aspirin-induced bleeding should be considered.